Browse ERBB2IP

Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction, hemidesmosome Nucleus membrane Basolateral cell membrane Note=Found in hemidesmosomes, which are cell-substrate adhesion complexes in stratified epithelia. In transfected cells, either diffusely distributed over the cytoplasm or concentrated at the basolateral membrane. Colocalizes with the adrenergic receptors, ADREN1A and ADREN1B, at the nuclear membrane of cardiac myocytes (By similarity).
Domain PF13855 Leucine rich repeat
PF00595 PDZ domain (Also known as DHR or GLGF)
Function

Acts as an adapter for the receptor ERBB2, in epithelia. By binding the unphosphorylated 'Tyr-1248' of receptor ERBB2, it may contribute to stabilize this unphosphorylated state (PubMed:16203728). Inhibits NOD2-dependent NF-kappa-B signaling and proinflammatory cytokine secretion (PubMed:16203728).

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002683 negative regulation of immune system process
GO:0002753 cytoplasmic pattern recognition receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0007163 establishment or maintenance of cell polarity
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007229 integrin-mediated signaling pathway
GO:0008105 asymmetric protein localization
GO:0016049 cell growth
GO:0030522 intracellular receptor signaling pathway
GO:0031349 positive regulation of defense response
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032495 response to muramyl dipeptide
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032642 regulation of chemokine production
GO:0032682 negative regulation of chemokine production
GO:0034612 response to tumor necrosis factor
GO:0035088 establishment or maintenance of apical/basal cell polarity
GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
GO:0038127 ERBB signaling pathway
GO:0038128 ERBB2 signaling pathway
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045103 intermediate filament-based process
GO:0045104 intermediate filament cytoskeleton organization
GO:0045175 basal protein localization
GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0061245 establishment or maintenance of bipolar cell polarity
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway
GO:0070424 regulation of nucleotide-binding oligomerization domain containing signaling pathway
GO:0070425 negative regulation of nucleotide-binding oligomerization domain containing signaling pathway
GO:0070431 nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0070432 regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0070433 negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0071356 cellular response to tumor necrosis factor
GO:0071605 monocyte chemotactic protein-1 production
GO:0071637 regulation of monocyte chemotactic protein-1 production
GO:0071638 negative regulation of monocyte chemotactic protein-1 production
GO:1901652 response to peptide
GO:1902532 negative regulation of intracellular signal transduction
Molecular Function GO:0005176 ErbB-2 class receptor binding
GO:0005178 integrin binding
GO:0005200 structural constituent of cytoskeleton
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005635 nuclear envelope
GO:0009925 basal plasma membrane
GO:0016323 basolateral plasma membrane
GO:0030055 cell-substrate junction
GO:0030056 hemidesmosome
GO:0031965 nuclear membrane
GO:0044420 extracellular matrix component
GO:0045178 basal part of cell
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
Reactome -
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ERBB2IP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ERBB2IP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.55 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ERBB2IP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1240.585
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0011
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2130.874
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0730.852
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0870.972
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2770.93
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1040.809
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3120.875
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1490.947
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1260.923
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7610.687
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 6823001
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ERBB2IP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ERBB2IP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ERBB2IP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ERBB2IP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ERBB2IP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ERBB2IP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ERBB2IP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolERBB2IP
Nameerbb2 interacting protein
Aliases ERBIN; densin-180-like protein; ERBB2-interacting protein; HEL-S-78; epididymis secretory protein Li 78; Pro ......
Chromosomal Location5p14.3-q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ERBB2IP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.